Follow and join the conversation with #EndAlz
According to the Alzheimer’s Association (@alzassociation) 55 million people worldwide are living with Alzheimer’s and other dementias. June is Alzheimer’s and Brain Awareness Month and this week’s Friday Five is dedicated to helping raise awareness and inspire action to support the fight against the disease.
Health UnaBASHEd: Diagnosing Alzheimer’s Sooner with ALZpath CEO Mike Banville
On this episode Gil and Gregg welcome Mike Banville, CEO of Alzpath, to discuss the critical need for early and accessible Alzheimer’s diagnostics. Alzpath is pioneering a blood-based biomarker test for Alzheimer’s that has the potential to transform how—and when—this devastating disease is detected. This episode is a must-listen for healthcare professionals, caregivers, policymakers, and anyone interested in the intersection of biotechnology, aging, and public health. Learn why Alzpath’s technology could soon be as routine as checking cholesterol—and why that could change millions of lives.
NeuroEM Therapeutics® Closes Initial Rounds in $5 Million Equity Raise to Commercialize Drug-free Alzheimer’s Treatment
NeuroEM Therapeutics®, a clinical-stage biotechnology research company pioneering the use of radio frequencies to reverse Alzheimer’s disease, has closed initial rounds totaling $1.33 million of a $5 million equity raise with BlueLake.vc. The Series A round supports continued progress toward commercialization of NeuroEM’s Transcranial Electromagnetic Treatment (TEMT-RF) to prevent and treat cognitive decline caused by aging or Alzheimer’s and other neurodegenerative diseases.
FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease
The U.S. Food and Drug Administration recently cleared for marketing the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer’s disease. The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is for the early detection of amyloid plaques associated with Alzheimer’s disease in adult patients, aged 55 years and older, exhibiting signs and symptoms of the disease.
Today, the FDA cleared for marketing the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer’s disease. This is for the early detection of amyloid plaques associated with Alzheimer’s disease in adult patients, aged 55 years and older, exhibiting signs… pic.twitter.com/8Dpj2QTbG8
— U.S. FDA (@US_FDA) May 16, 2025
Gerontologist Offers Lifeline to Families Caring for Loved Ones with Alzheimer’s as Diagnoses Increase
The physical, emotional and financial burden of Alzheimer’s and dementia on individuals and their caregivers cannot be overstated, says gerontologist and licensed social worker Dr. Macie P. Smith. And according to the latest statistics from the Alzheimer’s Association, that burden is growing — and growing fast. Dr. Smith’s latest book, A Dementia Caregiver Called to Action: The Journey, is a concise yet comprehensive resource designed to address common questions and offer valuable insights throughout the caregiving journey.
Rewriting the Timeline of Detection: Uncovering the Earliest Signs of Cognitive Decline
A pioneering study recently published in the Journal of Alzheimer’s Disease highlights how efficiently digital assessments can uncover the earliest signs of cognitive impairment—likely years before traditional testing methods or noticeable symptoms emerge. The narrative review and synthesis study is titled, “Precision neurocognition: An emerging diagnostic paradigm leveraging digital cognitive assessment technology.”
BONUS: Congress Must Continue to Invest in Alzheimer’s Research
Please urge your members of Congress to support an additional $113.485 million in Fiscal Year (FY) 2026 Alzheimer’s and dementia research funding at the National Institutes of Health (NIH) and to support $35 million in Fiscal Year (FY) 2026 for implementation of the BOLD Infrastructure for Alzheimer’s Act at the Centers for Disease Control and Prevention (CDC).
Join #alzforum Co-Chair Hector Montesino in telling Congress to invest an additional $113.485 million in Alzheimer’s and dementia research funding at the NIH and $35 million in implementing the #BOLDAlzheimersAct at the CDC. ➡️ https://t.co/b5ptNnMYzj pic.twitter.com/Lof8Rex5Tj
— Alzheimer’s Association (@alzassociation) June 10, 2025
ICYMI – Our other Friday Fives.
